Anticipate generic drug launch
Find generic entry opportunities
Proactively manage your pharmacy inventory
Drug patents …
… from Kazakhstan to Kalamazoo
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Manage your formulary budget
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Pharmaceutical composition for angiotensin II-mediated diseases|
|Abstract:||This invention relates to a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula ##STR1## wherein R.sup.1 is H or an optionally substituted hydrocarbon residue; R.sup.2 is an optionally esterified carboxyl group; R.sup.3 is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R.sup.2 ; and Y is a bond, --O--, --S(O)m-- (wherein m is 0, 1 or 2) or --N(R.sup.4)-- (wherein R.sup.4 is H or an optionally substituted alkyl group), or a pharmaceutically acceptable salt thereof in combination with a compound having diuretic activity or a compound having calcium antagonistic activity.|
|Inventor(s):||Inada; Yoshiyuki (Kawanishi, JP), Kubo; Keiji (Riverside, CA)|
|Assignee:||Takeda Chemical Industries, Ltd. (Osaka, JP)|
|Filing Date:||Jan 12, 2001|
|Claims:||1. A method for the prophylaxis or treatment of angiotensin II-mediated disease in a mammal in need thereof which comprises administering an effective amount of at least one of |
(.+-.)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7- carboxylate,
2-ethyoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7 -carboxylic acid, or
2-ethoxy-1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methy l]]-1H-benzimidazole-7-carboxylic acid, or a pharmaceutically acceptable salt thereof, in combination with an effective amount of furosemide.
2. A method according to claim 1, wherein the disease is hypertension, cardiac insufficiency, ischemic peripheral circulation disorders, myocardial ischemia, vein insufficiency, progressive cardiac insufficiency after myocardial infarction, diabetic nephritides, nephritis, arteriosclerosis, hyperaldosteronism, dermatosclerosis, glomerulosclerosis, renal insufficiency, central nervous system diseases, sensory disorders, Alzheimer's disease, deficiency of memory, depression, amnesia, senile dementia, anxiety neurosis, catatonia or indisposition, glaucoma, or intraocular high pressure.
3. A method according to claim 1, wherein the disease is hypertension.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.